Jove
Visualize
お問い合わせ

関連する概念動画

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

47
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
47
Drug Therapy01:28

Drug Therapy

346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
346
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

334
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
334
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

49
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
49
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

242
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
242
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Addressing Sub-Saharan Africa's Hypertension Care Crisis Through a Data-Driven Approach.

Journal of the American College of Cardiology·2025
Same author

Adapting Cardiovascular Disease Data to Inform Policy Goals: Global to Local.

Journal of the American College of Cardiology·2025
Same author

WHF Roadmap on Single Pill Combination Therapies.

Global heart·2025
Same author

Evaluating Blood Pressure Response Patterns to Exercise Stress Testing.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Low-Dose Combinations With 3 or 4 Blood Pressure-Lowering Medications for the Treatment of Hypertension.

JACC. Advances·2025
Same author

Consumer perceptions and preferences of pharmacist-led professional services and attributes in Australia: a qualitative focus group study.

BMJ open·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Mar 6, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K

ポリピルを実践する:課題と教訓

Ruth Webster1, Jose M Castellano2, Oyere K Onuma3

  • 1George Institute for Global Health, University of Sydney, Sydney, Australia.

Lancet (London, England)
|March 15, 2017
PubMed
まとめ
この要約は機械生成です。

心血管のポリピルは 患者のアデランスと 心臓病の危険因子を改善します 医療費の返済や医師の関与の欠如などの課題に直面し 公衆衛生上の恩恵を妨げています

さらに関連する動画

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

関連する実験動画

Last Updated: Mar 6, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.7K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

科学分野:

  • 心血管医学
  • 公衆衛生政策
  • 薬理学について

背景:

  • 心血管ポリピルの規制承認は 世界的に拡大しています
  • ポリピルは,心血管疾患または高リスクの患者で,アデレンスとリスクファクター制御の改善を示しています.
  • 既存の臨床試験データは,ポリピルの有効性と安全性を支持しています.

研究 の 目的:

  • 心血管ポリピルの臨床的影響と実施の課題を検討する.
  • 広範囲にわたる臨床採用と公衆衛生上の利益の実現の障壁を特定する.

主な方法:

  • ポリピル戦略に関する臨床試験文献の分析
  • 商用展開後の実用化体験のレビュー
  • 医師の採用と政府の補償に影響を与える要因の評価

主要な成果:

  • ポリピルは従来の治療と比較して,アデレンスと心血管リスクファクターのコントロールを大幅に改善します.
  • ポリピルの使用の費用対効果と安全性は,臨床的証拠によって支持されています.
  • 実施の主要障壁は政府の補償不足と医師の採用率の低さです.

結論:

  • 心血管ポリピルは臨床上大きな利点がありますが,現実の世界での実施には大きな障害があります.
  • 障壁を乗り越えるには 教育,提唱,政策改革の 協調的な努力が必要です
  • 世界各国の機関や国家機関や政府は ポリピルの統合を承認し 支援しなければなりません 公共衛生への影響を最大限に高めるためです